4M Therapeutics Presented Preclinical Data at the 26th Annual Conference of the International Society for Bipolar Disorders
Skillman, NJ – October 1, 2024 – 4M Therapeutics Inc., an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative conditions, today announced an oral presentation at the 26th Annual Conference of the International Society for Bipolar Disorders, which took place from September 29 to October 1, 2024, in Reykjavik, Iceland. The presentation, titled “Novel Small Molecule Inhibitors of GSK3β for the Treatment of Bipolar Disorder,” was presented by Dr. Pablo Lapuerta, CEO, on October 1, 2024.
The presentation examined the effects of lithium and two of 4M Therapeutics’ novel, small molecule GSK3B inhibitors on amphetamine-induced positive ultrasonic vocalizations (USVs), a validated model of positive affective state. Results showed that 4M’s novel GKS3B inhibitors had comparable efficacy to lithium, with marked increases in USVs with AMP attenuated by lithium, 4MT-A, and 4MT-B. The magnitude of reduction in flat USVs was generally 40-80%, depending on time interval, dose, and type of tone. In addition, animal safety data for 4MT-A indicates it has the potential to avoid the renal toxicity of lithium, and combined with its efficacy data, supports its advancement into clinical development for bipolar disorder.
About 4M Therapeutics Inc.
4M Therapeutics Inc. (4MTx) is advancing treatments for neuropsychiatric and neurodegenerative conditions. The Company focuses on targets for a wide array of disorders and indications. 4MTx applies unique insights from its living human brain cell platform, which was developed through a collaboration between Harvard, MIT, and the University of Washington to identify and design more effective and safer therapeutics. The Company’s pipeline includes potential breakthrough treatments for bipolar mania, agitation in Alzheimer’s disease, neurodegeneration, and other CNS disorders. For more information, visit www.4mtx.net.
For investor and media inquiries, please contact:
Kimberly Lee, DO
Chief Business Officer